Can gallium-68 compounds partly replace 18F-FDG in PET molecular imaging?

Hellenic Journal of Nuclear Medicine

Volumn 12, Issue 2, 2009, Pages

  Pagou, Margarita ^b   Zerizer, Imene ^b   Al Nahhas, Adil ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b NONE

Author keywords

Gallium 68; Neuroendocrine tumours; Peptides; Somatostatin receptors

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 NAL OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ALPHA MELANOCYTE STIMULATING HORMONE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ALPHA MELANOCYTE STIMULATING HORMONE RHENIUM GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID NAPAMIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PESIN GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID RHENIUM GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSYLTHREONINE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID VASCULAR ADHESION PROTEIN 1 GA 68; BOMBESIN RECEPTOR; DISOPYRAMIDE; ETHYLENE DICYSTEINE METRONIDAZOLE GA 68; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; METRONIDAZOLE; METRONIDAZOLE GA 68; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL TUMOR; ANIMAL TESTING ALTERNATIVE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; GASTRINOMA; HUMAN; HYPOXIA; IN VITRO STUDY; INSULINOMA; MELANOMA; MENINGIOMA; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING;

FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; IMAGE ENHANCEMENT; MOLECULAR PROBE TECHNIQUES; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 69249196092     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. 18F-radiopharmacy. Ernst Schering Res Found Workshop 2007; 62:215-242.
2. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008; 3:67-77.
3. Antunes P, Ginj M, Zhang H et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nud Med Mol Imaging 2007; 34:982-993.
4. th edn. New York: Oxford University Press; 2006.
5. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20:157-198.
6. th edn. New York: Oxford University Press; 2006.
7. Gardiner J, Langenegger D, Hoyer D et al. The enantiomer of octreotate binds to all five somatostatin receptors with almost equal micromolar affinity-a comparison with SANDOSTATIN. Chem Biodivers 2008;5: 1213-1224.
8. th edn. New York: Oxford University Press; 2006.
9. rd edn. Churchill Livingstone: Elsevier Limited; 2004.
10. Wild D, Schmitt JS, Ginj M et al. DOTA-NOC, a high affiniy ligand of somatostatin receptor subtypes 2,3 and 5 for labelling with various radiometals. Eur J Nud Med Mol Imaging 2003; 30:1338-1347. (Pubitemid 37247950)
11. 68 Ga DOTATATE PET in malignant abdominal paraganglioma. Eur J N Med Mol Imaging 2006;33:506.
12. Schonbrunn A. Somatostatin receptors: present knowledge and future directions. Ann Oncol 1999; 10 Suppl 2: S17-S21. (Pubitemid 29288526)
13. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging 2003; 30: 781-793. (Pubitemid 36612963)
14. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor SST1-SST5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28:836-846. (Pubitemid 32662546)
15. Reubi JC, Schar JC, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282. (Pubitemid 30167697)
16. AL-Nahhas A, Win Z, Szyszko T etal. What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 2007; 34:1897-1901.
17. Cescato R, Schulz S, Waser B et al. Internalization of SST2, SST3, and SST5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med Med 2006; 47:502-511.
18. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751-1757. (Pubitemid 33141238)
19. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5:42-48.
20. 3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT. J Nucl Med 2007; 48:508-518.
21. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33:460-466.
22. 68Ga-DOTATATE PET imaging in neuroendocrine and neuroectodermal tumours. Nucl Med Commun 2006; 27:288.
23. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007; 28: 359-363.
24. 3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005; 46:763-769. (Pubitemid 43750751)
25. 68Ga]- DOTATOC-PET. Int J Radiât Oncol Biol Phys 2006; 65:222-227.
26. 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med 2004; 45:347-355. (Pubitemid 47618660)
27. Wei L, Miao Y, Gallazzi F et al. Gallium-68-labeled DOTA-rheniumcyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol 2007; 34:945-953.
28. Froidevaux S, Calame-Christie M, Schuhmacher J et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004; 45:116-123. (Pubitemid 47611617)
29. 14] bombesin(6-14). Clin Cancer Res 2002; 8:1139-1146.
30. Zhang H, Schuhmacher J, Waser B et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007; 34:1198-1208. (Pubitemid 47296770)
31. Ito M, Yang DJ, Mawlawi O et al. PET and planar imaging of tumor hypoxia with labelled metronidazole. Acad Radiol 2006; 13: 598-609.
32. 68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 2005; 46:354-364. (Pubitemid 43073447)
33. 18F-FDG-PET, in patients with low grade gliomas. Hell J Nucl Med 2008; 11:149-152.
34. 68Ga-DOTAVAP-PI PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur J Nucl Med Mol Imaging 2008; 35:352-364.
35. 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging 2005; 32: 1259-1268. (Pubitemid 41598716)
36. Strauss LG, Dimitrakopoulou-Strauss A. The role of PET in head and neck cancer. Hell J Nucl Med 2008; 11:6-11. (Pubitemid 351649750)
37. Dimitrakopoulou-Strauss A, Strauss LG. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients. Hell J Nucl Med 2006; 9:10-21.